Development and validation of uv spectrophotometric method for simultaneous estimation of montelukast sodium and bambuterol hydrochloride in bulk and tablet dosage formulation

Abstract EN

Montelukast is leukotrine receptor blocker and bambuterol is β2 receptor agonist, and a combination of these drugs is used in the management of asthma.

A simple, precise, rapid and selective simultaneous equation by corrective absorbance method has been developed and validated for the simultaneous determination of montelukast and bambuterol in bulk and marketed tablet formulation.

The method involves solving the simultaneous equation by calculating the concentration of one analyte in the sample and the concentration of the second absorbing component of interest which was then calculated from the corrected absorbance (total absorbance minus absorbance of the interfering substances) in the usual way.

Methanol was used as a solvent, the wavelength maxima of montelukast and bambuterol was found to be 283 nm and 265 nm, respectively.

The absorptivity of montelukast at 283 and 265 nm was calculated and found to be 383.15 and 285.67 g-1L cm-1 respectively, for bambuterol at 265 nm it was 10.68 g-1L cm-1, while at 283 nm, bambuterol has very negligible absorptivity.

An equation was derived to calculate the concentration of montelukast and bambuterol in combined tablet formulation simultaneously.

Montelukast and bambuterol were found to be linear in the concentration range of 10- 80 μgmL-1 and 40 – 240 μgmL-1, respectively.

The method was found sensitive, accurate and precise for simultaneous estimation of montelukast and bambuterol in combined tablet dosage forms.